HIV 1994 to 2017: How far have we come?

A new analysis of outcomes in almost 78,000 people living with HIV (PLHIV), shows that the efficacy of first-line antiretroviral therapy (ART) continues to improve. However, the findings also highlight that phase 3 studies overestimate ‘real world efficacy’ and longer phase 4 studies in both resource-rich and resource-limited settings are required.1